Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
Martine J PiccartMarion ProcterDebora FumagalliEvandro de AzambujaEmma ClarkMichael S EwerEleonora RestucciaGuy JerusalemSusan F DentLinda ReabyHervé R BonnefoiIan E KropTsang-Wu LiuTadeusz PieńkowskiMasakazu ToiNicholas WilckenMichael AnderssonYoung-Hyuck ImLing Ming TsengHans-Joachim LueckMarco ColleoniEstefania MonturusMihaela SicoeSébastien GuillaumeJose BinesRichard D GelberGiuseppe VialeChristoph Thomssennull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
This analysis confirms the IDFS benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early BC. Longer follow-up is needed to fully assess OS benefit.